Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven intracranial glioblastoma multiforme with pathologic or imaging confirmation of tumor progression or regrowth after failure of two previous treatment regimens~* Initial low-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma~* History and physical exam, including neurologic examination, within 4 weeks prior to registration~Exclusion Criteria:~• Warfarin or LMW heparin patients must have no active bleeding or pathological condition that carries a high risk of bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Fractionated Radiosurgery and Bevacizumab (Type: EXPERIMENTAL): FRS and Bev followed by Bev combined either Irinotecan or Temozolamide or Carboplatin or Etoposide until progression
- Bev with Chemo (Type: ACTIVE_COMPARATOR): Bev combined either Irinotecan or Temozolomide or Carboplatin or Etoposide until progression

Based on this trial design, predict the completion outcome and termination type (if applicable).